Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO, June 10, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry.
"While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials," said Tom Miller, PhD, Iambic's co-founder and CEO. "Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas."
Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases.
Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale.
"We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. "Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals."
The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process.
For the complete list of CNBC Disruptor 50 companies, visit cnbc.com/disruptors.
About Iambic's AI-Driven Discovery Platform
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence.
About Iambic Therapeutics
Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at Iambic.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610916531/en/
Contacts
media@Iambic.ai
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Bay Psychiatric Associates Hosts Open House for Healthcare Providers
SAN MATEO, Calif.--(BUSINESS WIRE)--Bay Psychiatric Associates is excited to announce a successful Open House event at its newly expanded San Mateo location, held on Wednesday, May 7th, 2025. This event welcomed healthcare providers interested in learning more about the clinic's comprehensive mental health services, including Ketamine/Spravato, Transcranial Magnetic Stimulation (TMS), and Outpatient Services such as Psychotherapy and Medication Management. We're thrilled to open our doors to healthcare providers in the community and share the innovative treatments we offer to help individuals manage mental health conditions. Share Founded in 1994, Bay Psychiatric Associates has long been a trusted leader in mental health care in the Bay Area. To meet the growing demand for advanced treatment options, the clinic has expanded its services. The multidisciplinary team, including psychiatrists and dedicated support staff, works collaboratively to ensure patients receive effective, accessible, and compassionate care. The Open House featured guided tours of the facility, opportunities to meet the clinic's medical and administrative staff, and an in-depth overview of the latest in psychiatric care. Hors d'oeuvres and refreshments were provided, and the event also served as a networking opportunity for local healthcare professionals to connect and discuss potential referral partnerships. 'We're thrilled to open our doors to healthcare providers in the community and share the innovative treatments we offer to help individuals manage mental health conditions,' said Dr. Roberto Estrada, Interventional Psychiatry Medical Director at Bay Psychiatric Associates. 'Our team has worked tirelessly to ensure that our services are not only effective but also accessible to those who need them most. We look forward to discussing these advancements with our colleagues in the healthcare field.' About Bay Psychiatric Associates Bay Psychiatric Associates is a leading mental health provider in the Bay Area, specializing in innovative treatments for mental health conditions, including Transcranial Magnetic Stimulation (TMS), Spravato (esketamine), and ketamine therapy. The clinic's multidisciplinary team is dedicated to providing the highest quality care to patients struggling with depression, anxiety, and other mental health disorders. Outpatient clinics are located in Berkeley, San Francisco, Corte Madera, and San Mateo. Learn more via our website.
Business Wire
2 hours ago
- Business Wire
Resecurity Appoints Luiz Cota as Territory Manager for Brazil
LOS ANGELES--(BUSINESS WIRE)-- Resecurity, Inc., a global leader in cybersecurity and threat intelligence solutions, is pleased to announce the appointment of Luiz Cota as Territory Manager for Brazil. With more than three decades of experience in technology and cybersecurity across Latin America, Cota will spearhead Resecurity's efforts to expand its footprint in Brazil and strengthen cyber defense capabilities for local enterprises, public institutions, and critical infrastructure. Throughout his career, Luiz Cota has held senior roles at leading cybersecurity and technology firms including Cisco, IronPort, SurfControl, Fidelis, and Offensive Security. His extensive background in both commercial and technical domains positions him to effectively adapt and deliver Resecurity's advanced threat intelligence solutions to meet the unique needs of the Brazilian market. Cota brings a rare combination of deep technical expertise and strategic business insight. He founded Brazil's first cyber-insurance brokerage, advising startups and established enterprises on cyber risk mitigation, threat modeling, and digital resilience. With a clear understanding of Brazil's regulatory framework, digital economy, and emerging threat landscape, he is uniquely equipped to help organizations implement localized, intelligence-driven cybersecurity strategies. 'Luiz offers a profound understanding of the Brazilian cybersecurity landscape and a proven ability to execute complex go-to-market strategies,' said Gene Yoo, CEO of Resecurity. 'His leadership will be key as we accelerate our growth in Latin America and support Brazilian organizations in building stronger defenses against rapidly evolving cyber threats.' Luiz Cota holds a degree in Electronic Engineering, a specialization in marketing, and an MBA, enabling him to bridge the gap between technical innovation and business execution. He will lead Resecurity's regional initiatives in partnership development, threat intelligence delivery, and customer success, with a focus on empowering local partners and clients to anticipate, detect, and respond to cyber risks with greater precision. 'Cybersecurity has become a strategic priority in Brazil as digital transformation advances across all sectors,' said Luiz Cota. 'I'm excited to join Resecurity and bring world-class cyber intelligence capabilities to organizations committed to protecting their data, infrastructure, and people.' This appointment marks a significant step in Resecurity's regional expansion strategy, reinforcing its commitment to providing scalable, proactive, and locally relevant cybersecurity solutions throughout Latin America. About Resecurity Resecurity® is a cybersecurity company that delivers a unified endpoint protection, fraud prevention, risk management, and cyber threat intelligence platform. Known for providing best-of-breed data-driven intelligence solutions, Resecurity's services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, by Inc. Magazine, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California. As a member of InfraGard National Members Alliance (INMA), AFCEA, NDIA, SIA, FS-ISAC, and the American Chamber of Commerce in Saudi Arabia (AmChamKSA), Singapore (AmChamSG), Korea (AmChamKorea), Mexico (AmChamMX), Thailand (AmChamThailand), and UAE (AmChamDubai). To learn more about Resecurity, visit
Business Wire
2 hours ago
- Business Wire
Mogo Announces Results of its Annual General Meeting of Shareholders
VANCOUVER, British Columbia--(BUSINESS WIRE)--The annual general meeting of shareholders (the "Meeting") of Mogo Inc. (NASDAQ: MOGO) (TSX: MOGO;) ("Mogo" or the "Company"), a digital wealth and payments business, was held today via live audiocast online and the Company is pleased to announce that all resolutions put forward, being the election of directors, the appointment of the auditors of the Company, and the renewal of the Company's stock option plan and all unallocated options thereunder, were approved. Each of the matters voted upon at the Meeting is discussed in detail in the Company's management information circular dated June 4, 2025 (the 'Circular'), which can be found under the Company's profile on SEDAR+ ( The total number of votes cast by shareholders by proxy or online at the Meeting was 9,529,647 votes, representing 38.94% of the Company's outstanding shares as at May 23, 2025. The voting results are detailed below. Election of Directors The nominees listed in the Circular were elected as directors of Mogo. Detailed results of the vote are as follows: Name of Nominee Votes For % Votes For Votes Withheld % Votes Withheld David Feller 6,744,975 97.55 169,436 2.45 Gregory Feller 6,744,490 97.54 169,921 2.46 Alex Shan 5,947,760 86.02 966,651 13.98 Christopher Payne 4,720,033 68.26 2,194,378 31.74 Kees van Winters 4,709,670 68.11 2,204,742 31.89 Kristin McAlister 4,710,470 68.13 2,203,942 31.87 Expand Appointment of Auditor MNP LLP was re-appointed as auditor of the Company until the next annual general meeting of shareholders of the Company at remuneration to be fixed by the Company's board of directors. Detailed results of the vote are as follows: Approval of Unallocated Options The Company's Stock Option Plan and all unallocated options under the Company's Stock Option Plan were renewed. Detailed results of the vote are as follows: The Company has filed a report of voting results on all resolutions voted upon at the Meeting under its profile on SEDAR+ at About Mogo Mogo Inc. (NASDAQ:MOGO; TSX:MOGO) is a financial technology company with three distinct business lines: wealth, lending, and payments. Our mission is to provide consumers with innovative financial solutions that drive long-term financial health and success. We operate with a differentiated approach in each business, leveraging technology, behavioral science, and financial tools to create unique value propositions in our respective markets. Our wealth and lending businesses are focused on the Canadian market, where we are the only subprime consumer lender that also offers a holistic wealth and investing solution. This unique integration is designed to help consumers transition from borrowing and debt to long-term wealth building. Separately, our payments business is operated through Carta Worldwide, a wholly owned subsidiary that provides modern card issuing and processing solutions, primarily in Europe.
